BioCorRx, Inc., formerly Fresh Start Private Management, Inc., is a holding company. The Company is an addiction healthcare solutions company operating in Santa Ana, California. The Company, through its subsidiary, Fresh Start Private, Inc., provides alcoholism and opioid treatment program. It offers a medication-assisted treatment program that combines non-addictive medication coupled with psycho-social counseling. It also distributes and licenses the BioCorRx Recovery Program for alcoholism and opioid addiction treatment. The BioCorRxO Recovery Program consists of over two parts, which include an implant, administered by a licensed physician, of a compounded formulation of the drug, Naltrexone (implanted under the skin) (the Implant), which reduces alcohol cravings over a period of time, and a structured, intensive one on one counseling program developed by it. It offers BioCorRx Recovery Program in over 10 locations, including California, Arizona, Atlanta, Illinois and others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:BICX
- CUSIP: N/A
- Web: www.biocorrx.com
Capitalization:- Market Cap: $22.77 million
- Outstanding Shares: 239,711,000
Average Prices:- 50 Day Moving Avg: $0.11
- 200 Day Moving Avg: $0.12
- 52 Week Range: $0.01 - $0.34
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $605,585.00
- Price / Sales: 37.60
- Book Value: ($0.18) per share
- Price / Book: -0.52
Profitability:Debt:- Debt-to-Equity Ratio: -0.02%
- Current Ratio: 1.15%
- Quick Ratio: 1.15%
Misc:- Average Volume: 660,229 shs.
- Beta: 0.31
Frequently Asked Questions for Biocorrx (OTCMKTS:BICX)
What is Biocorrx's stock symbol?
Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."
How were Biocorrx's earnings last quarter?
Biocorrx Inc. (OTCMKTS:BICX) announced its earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business earned $0.17 million during the quarter. View Biocorrx's Earnings History.
Who are some of Biocorrx's key competitors?
Some companies that are related to Biocorrx include Ekso Bionics Holdings (EKSO), Histogenics Corporation (HSGX), BioLife Solutions (BLFS), AEterna Zentaris (AEZS), Auris Medical Holding AG (EARS), Evoke Pharma (EVOK), Biocept (BIOC), Marinus Pharmaceuticals (MRNS), Presbia PLC (LENS), Trillium Therapeutics (TRIL), Orexigen Therapeutics (OREX), Prima BioMed Ltd (PBMD), Ohr Pharmaceuticals (OHRP), Nivalis Therapeutics (NVLS), ContraVir Pharmaceuticals (CTRV), TRACON Pharmaceuticals (TCON), Bio-Path Holdings (BPTH) and Cytori Therapeutics (CYTX).
Who are Biocorrx's key executives?
Biocorrx's management team includes the folowing people:
- Brady J. Granier, President, Chief Executive Officer, Director
- Lourdes Felix, Chief Financial Officer, Chief Operating Officer, Treasurer, Director
- Tom Welch, Director - Operations
- Kent Emry, Director
How do I buy Biocorrx stock?
Shares of Biocorrx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocorrx's stock price today?
One share of Biocorrx stock can currently be purchased for approximately $0.10.
MarketBeat Community Rating for Biocorrx (OTCMKTS BICX)MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Biocorrx (OTCMKTS:BICX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Biocorrx (OTCMKTS:BICX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Biocorrx (OTCMKTS:BICX)Earnings History by Quarter for Biocorrx (OTCMKTS BICX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/17/2016 | Q3 2016 | | ($0.02) | | $0.17 million | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for Biocorrx (OTCMKTS:BICX)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Biocorrx (OTCMKTS:BICX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biocorrx (OTCMKTS:BICX)Insider Ownership Percentage: 14.85%
Insider Trades by Quarter for Biocorrx (OTCMKTS:BICX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/27/2015 | Jorge Andrade Jr | Director | Sell | 125,000 | $0.06 | $7,500.00 | |
| 2/26/2015 | Jorge Andrade Jr | Director | Sell | 245,000 | $0.05 | $12,250.00 | |
| 2/23/2015 | Jorge Andrade Jr | Director | Sell | 215,000 | $0.06 | $12,900.00 | |
| 2/17/2015 | Jorge Andrade Jr | Director | Sell | 90,000 | $0.08 | $7,200.00 | |
| 2/10/2015 | Jorge Andrade Jr | Director | Sell | 60,000 | $0.09 | $5,400.00 | |
| 10/28/2014 | Jorge Andrade Jr | Director | Sell | 25,000 | $0.09 | $2,250.00 | |
| 10/13/2014 | Jorge Andrade Jr | Director | Sell | 80,000 | $0.09 | $7,200.00 | |
| 10/7/2014 | Jorge Andrade Jr | Director | Sell | 40,000 | $0.11 | $4,400.00 | |
| 10/1/2014 | Jorge Andrade Jr | Director | Sell | 30,000 | $0.13 | $3,900.00 | |
| 9/29/2014 | Jorge Andrade Jr | Director | Sell | 170,000 | $0.10 | $17,000.00 | |
| 9/22/2014 | Jorge Andrade Jr | Director | Sell | 130,000 | $0.10 | $13,000.00 | |
| 9/15/2014 | Jorge Andrade Jr | Director | Sell | 90,000 | $0.10 | $9,000.00 | |
| 9/8/2014 | Jorge Andrade Jr | Director | Sell | 95,000 | $0.11 | $10,450.00 | |
| 8/22/2014 | Jorge Andrade Jr | Director | Sell | 100,000 | $0.13 | $13,000.00 | |
| 8/14/2014 | Jorge Andrade Jr | Director | Sell | 300,000 | $0.14 | $42,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Biocorrx (OTCMKTS:BICX)
Latest Headlines for Biocorrx (OTCMKTS:BICX)
| Source: |
|
| Date | Headline |
|---|
 | BioCorRx Announces First Addiction Treatment Center in South Florida to Implement the BioCorRx Program
finance.yahoo.com - July 21 at 6:11 PM |
| BioCorRx to Exhibit at ASAM Conference in Dallas, Texas
finance.yahoo.com - July 6 at 4:07 PM |
| BioCorRx CEO Brady Granier Appears on Fox 11 Morning News Los Angeles; Anaheim Residents Encouraged to Seek Treatment
finance.yahoo.com - June 8 at 4:41 PM |
 | BioCorRx Inc.: BioCorRx to Present at the 2017 Marcum Microcap Conference
www.finanznachrichten.de - June 7 at 4:13 PM |
| BioCorRx to Present at the 2017 Marcum Microcap Conference
finance.yahoo.com - June 7 at 9:49 AM |
| BioCorRx Partners with the Virtual Reality Medical Center and Physicians at Scripps Memorial Hospital for Naltrexone Implant Study, Grant Assistance and Strategic Partnerships
finance.yahoo.com - June 1 at 4:21 PM |
| BioCorRx to Host Grand Opening Ribbon Cutting, Support Drug Free Anaheim Initiative in the City of Anaheim
finance.yahoo.com - May 30 at 12:23 PM |
| BioCorRx Granted Pre-IND Meeting with FDA for BICX101
finance.yahoo.com - May 25 at 5:01 PM |
| BioCorRx Submits Listing Application for the NASDAQ Capital Market
finance.yahoo.com - May 16 at 12:38 PM |
| BioCorRx Provides Business Update for the First Quarter of 2017
finance.yahoo.com - May 15 at 9:04 AM |
| BioCorRx CEO Brady Granier Appears on Fox & Friends
finance.yahoo.com - May 3 at 6:38 PM |
| BioCorRx Collaborating with DynamiCare Health to Develop Mobile Application for Patients with Opioid and Alcohol Addiction
finance.yahoo.com - April 24 at 10:09 AM |
| BioCorRx Submits Meeting Request for Pre-IND Meeting with FDA for BICX101
finance.yahoo.com - April 10 at 11:43 AM |
| BioCorRx Announces BICX101 Preclinical Update; ASAM Attendance
finance.yahoo.com - April 7 at 8:30 AM |
| Private Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx
finance.yahoo.com - April 2 at 3:47 PM |
| BioCorRx CEO Brady Granier Appears on Fox Business Network
finance.yahoo.com - March 28 at 1:08 PM |
| Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with SmallCapVoice.com
finance.yahoo.com - March 27 at 11:10 AM |
| BioCorRx Announces Upgrade to the OTCQB(R)
finance.yahoo.com - March 22 at 3:35 PM |
| BioCorRx Announces Updates on Preclinical Studies of BICX101 and Pre-IND Meeting Request with FDA
finance.yahoo.com - March 21 at 4:15 PM |
| BioCorRx to Present at the Sidoti & Company Spring 2017 Convention in NYC
finance.yahoo.com - March 15 at 4:13 PM |
| BioCorRx Completes $940,000 Equity Financing and Announces Alpine Creek Capital has Agreed to Invest an Additional $1.7 Million
finance.yahoo.com - March 10 at 4:45 PM |
| America's War on Drugs
finance.yahoo.com - March 7 at 12:35 PM |
| Who Is Winning the Fight Against Opioid Abuse?
finance.yahoo.com - February 27 at 3:20 PM |
| BioCorRx Provides Preclinical Study Update on BICX101 Development
finance.yahoo.com - February 23 at 3:21 PM |
| Drug Addiction Treatment Stocks to Watch
finance.yahoo.com - February 22 at 3:56 PM |
| BioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development
finance.yahoo.com - February 21 at 10:41 AM |
| ANGEL Program Gets National Attention
finance.yahoo.com - February 13 at 4:25 PM |
| BioCorRx Provides Business Update Webcast
finance.yahoo.com - February 10 at 3:23 PM |
| BIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 8 at 4:04 PM |
| BioCorRx to Collaborate with the City of Anaheim to Treat Opioid and Alcohol Addiction
finance.yahoo.com - February 8 at 4:04 PM |
 | 21st Century Cures Act Hopes To Reduce $41 Billion Annual Cost Of Opioid Treatments
seekingalpha.com - January 22 at 3:53 PM |
| JGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of $0.09
finance.yahoo.com - January 19 at 8:24 PM |
| BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone Products
finance.yahoo.com - January 12 at 4:09 PM |
| BioCorRx Inc. to Present at the 9th Annual LD Micro Main Event
finance.yahoo.com - December 2 at 10:13 AM |
| BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA
finance.yahoo.com - November 29 at 2:57 PM |
| BioCorRx Inc. to Host Corporate Update Webinar on Wednesday, October 12th at 2:00 p.m. Eastern Time
finance.yahoo.com - October 6 at 9:21 AM |
| BioCorRx Inc. Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product
finance.yahoo.com - September 15 at 12:44 PM |
| BioCorRx Inc. Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology
finance.yahoo.com - August 31 at 3:49 PM |
| BioCorRx, Inc. Announces Agreement With Dr. David Gastfriend to Provide Strategic Initiative and Corporate Development Consulting
finance.yahoo.com - August 17 at 12:00 PM |
| BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - August 3 at 12:30 PM |
| BioCorRx Retains MZ Group as Investor Relations Advisor
finance.yahoo.com - July 20 at 10:28 AM |
| BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant
finance.yahoo.com - July 14 at 8:00 AM |
| Alpine Creek and BioCorRx Announce Major Investment Into BioCorRx
finance.yahoo.com - June 20 at 2:01 PM |
| BIOCORRX INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statemen
biz.yahoo.com - May 20 at 5:05 PM |
| BIOCORRX INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - April 18 at 4:13 PM |
| BIOCORRX INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - April 14 at 2:55 PM |
| BioCorRx's Program to Help Beat Alcohol and Opioid Addiction Now in 20 Locations and Growing in Time for Alcohol Awareness Month
finance.yahoo.com - April 4 at 8:24 AM |
Biocorrx (BICX) Chart for Sunday, July, 23, 2017
